RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models (vol 70, pg 5518, 2010)

被引：2
|
作者：
Yang, Hong
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷 / 22期
关键词：
D O I：
10.1158/0008-5472.CAN-10-3605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9527 / 9527
页数：1
相关论文
共 16 条
  • [1] RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Go, Zenaida
    Iyer, Raman
    Kolis, Stanley
    Zhao, Sylvia
    Lee, Richard
    Grippo, Joseph F.
    Schostack, Kathleen
    Simcox, Mary Ellen
    Heimbrook, David
    Bollag, Gideon
    Su, Fei
    CANCER RESEARCH, 2010, 70 (13) : 5518 - 5527
  • [2] The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
    Xing, Joanna
    Liu, Ruixin
    Xing, Mingzhao
    Trink, Barry
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 404 (04) : 958 - 962
  • [3] PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models
    Su, Fei
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Lee, Richard
    Packman, Kathryn
    Schostack, Kathleen
    Heimbrook, David
    Bollag, Gideon
    CANCER RESEARCH, 2009, 69
  • [4] The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
    Jenkins, Molly H.
    Croteauz, Walburga
    Mullins, David W.
    Brinckerhoff, Constance E.
    MATRIX BIOLOGY, 2015, 48 : 66 - 77
  • [5] Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Sondergaard, Jonas N.
    Nazarian, Ramin
    Wang, Qi
    Guo, Deliang
    Hsueh, Teli
    Mok, Stephen
    Sazegar, Hooman
    MacConaill, Laura E.
    Barretina, Jordi G.
    Kehoe, Sarah M.
    Attar, Narsis
    von Euw, Erika
    Zuckerman, Jonathan E.
    Chmielowski, Bartosz
    Comin-Anduix, Begona
    Koya, Richard C.
    Mischel, Paul S.
    Lo, Roger S.
    Ribas, Antoni
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [6] Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes
    Meier, F. E.
    Beck, D.
    Niessner, H.
    Flaherty, K. T.
    Iovanna, J.
    Kulms, D.
    Schadendorf, D.
    Garbe, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
    Halaban, Ruth
    Zhang, Wengeng
    Bacchiocchi, Antonella
    Cheng, Elaine
    Parisi, Fabio
    Ariyan, Stephan
    Krauthammer, Michael
    McCusker, James P.
    Kluger, Yuval
    Sznol, Mario
    PIGMENT CELL & MELANOMA RESEARCH, 2010, 23 (02) : 190 - 200
  • [8] Molecular Testing for BRAF V600 Mutations in Clinical Trials of the BRAF Inhibitor Vemurafenib (RG7204/PLX4032) in Metastatic Melanoma - a Comparison With Sanger Sequencing
    Anderson, S.
    Bloom, K.
    Schilling, R.
    Lee, J. R. J.
    Langland, R.
    Halait, H.
    Lawrence, H. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S170 - S170
  • [9] Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model
    Higgins, Brian
    Kolinksy, Kenneth
    Go, Zenaida
    Char, Hing
    Lee, Richard
    Schostack, Kathleen
    Bollag, Gideon
    Heimbrook, David
    Su, Fei
    Packman, Kathryn E.
    CANCER RESEARCH, 2011, 71
  • [10] The analytic performance of a real-time PCR-based assay for the BRAF V600E mutation used as the companion diagnostic test for the novel BRAF inhibitor RG7204 (PLX4032) in metastatic melanoma
    Halait, Harkanwal
    DeMartin, Kelli
    Shah, Sweta
    Soviero, Stephen
    Langland, Rachel
    Cheng, Suzanne
    Hillman, Grantland
    Wu, Lin
    Lawrence, Jeffrey
    CANCER RESEARCH, 2011, 71
12